DEENOVA
Deenova announced today it keeps its record-breaking market momentum started in 2021, by winning competitive public tenders at Resah for 6 D3 ACCED Robots and multiple D3 Astus medication solutions to be operated around the clock at Nimes University Hospital , Centre Hospitalier Intercommunal Eaubonne Montmorency-Simone Veil in Sud Val d’Oise, and finally Centre Hospitalier Sainte-Marie Le Puy-en-Velay .
Christophe Jaffuel , Deenova Chief Commercial Officer, stated: “I am very proud France continues to lead Deenova’s international growth for 2 years in a row. Our team latest 3 competitive wins highlight Deenova main differentiating characteristics over our competition, especially in France: Patient Care Crafted for Better Safety and Greater Therapy Compliance , as well as 24/7 availability, a key component of customer needs”.
Loïc Bessin , Managing Director of Deenova in France stated: “I am delighted to welcome 3 new groups of hospital customers to the fast-growing Deenova family in Europe. It is indeed a huge milestone for our company and for our customers to witness first-hand the unparalleled and sustained recognition and success we are receiving over the last 2 years.”
Nimes University Hospital , founded in 1958, is a reference center of medical and surgical specialties, with the priorities of prevention, health education, access to care and fight against social exclusion.
Centre Hospitalier Intercommunal Eaubonne Montmorency-Simone Veil is a key public health player in the Val d'Oise Area with a diversified healthcare offer: medicine, surgery, residential facilities for dependent elderly people and a long-term care unit, psychiatric care, rehabilitation services, etc.
Centre Hospitalier Sainte-Marie Le Puy-en-Velay was created in 1850 by the nuns of the Congregation Sainte-Marie de L’Assomption de PRIVAS. The evolution of mental health care has led the hospital towards elderly, disabled adults and dependent people over the entire Haute-Loire, with home care services, therapeutic reception centers, mobile psychiatry, long-stay unit, etc.
Resah is a public interest group (GIP) created in 2007 to support the pooling of hospital purchases for the Ile-de-France region, in collaboration with Achat Hopital .
Deenova is the undisputed leading supplier of mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere.
Deenova’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff.
Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210505005485/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Expereo Appoints Noel Hamill as Chief Marketing Officer6.11.2025 10:00:00 CET | Press release
Expereo, the world-leading managed Network as a Service (NaaS) provider that connects people, places and things anywhere, today announces the appointment of Noel Hamill as its Chief Marketing Officer (CMO), a strategic hire to accelerate the company’s growth strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106364284/en/ Noel Hamill Hamill joins Expereo with over two decades of marketing leadership experience across global SaaS businesses and consumer brands, including EE and Ladbrokes, PG Forsta and most recently parcelLab, where he served as CMO. In his new role, Hamill will report directly to Ben Elms, CEO, and lead Expereo’s global marketing strategy with a sharp focus on driving growth, expanding market share, and scaling customer acquisition across enterprise and wholesale segments. His appointment underscores Expereo’s commitment to strengthening its brand presence and accelerating adoption of its expereoOne
Energy Transition Solutions Powered by Choice: Trilliant to Share Expertise and Knowledge with Utilities and Smart Cities at Enlit Europe 20256.11.2025 09:00:00 CET | Press release
Product demonstrations and presentations from subject matter experts will highlight key industry insights and the importance of smarter infrastructure to connect systems, empower choice, and unlock performance Trilliant, a leading international provider of solutions for advanced metering infrastructure (AMI), smart grid, smart cities and IIoT, will be an exhibitor, presenter, and Silver Sponsor at Enlit Europe 2025. With product demonstrations on the exhibition floor and compelling presentations from thought leaders, Trilliant will highlight the importance of energy transition solutions, all powered by choice — that are flexible, scalable and interoperable. Taking place November 18- 20, 2025 in Bilboa, Spain, at the Bilbao Exhibition Centre (BEC), Enlit Europe 2025 is an event designed to connect industries, inspire action, and help Europe evolve into a dependable, decarbonised, and digitalised energy system. “As utilities and smart cities across Europe advance their energy transition
Red Hat Introduces Confirmed Sovereign Support for European Union6.11.2025 09:00:00 CET | Press release
Dedicated, EU-citizen-driven support delivers localized operational control and resilience for digital sovereignty Red Hat, the world's leading provider of enterprise open source solutions, today announced Red Hat Confirmed Sovereign Support for the 27 member states of the European Union to address the critical strategic imperative for digital sovereignty in Europe. This new support offering is purpose-built to deliver dedicated EU-citizen-driven technical support from within the EU for Red Hat software subscriptions, providing a new level of verifiable local control over critical IT operations. More and more European business leaders are looking to digital sovereignty as a way to help drive economic differentiation in a global marketplace, as well as insulate operations from geopolitical dynamics and safeguard EU data, technology and operations. At the same time, these leaders want to further cloud infrastructure resiliency and AI innovation goals through strengthened supply chain tra
IFF Benicarló Pioneers On-Site Green Hydrogen Production Facility for Sustainable Fragrance Ingredient Manufacturing6.11.2025 09:00:00 CET | Press release
Local site sets a new benchmark for the fragrance industry IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients and biosciences, announced the installation of a nature-based hydrogen production facility at its Scent R&D and fragrance ingredients manufacturing plant in Benicarló, Spain. The site has partnered with Iberdrola, one of the world’s largest producers of renewable energy, to become the first in the fragrance industry to rely on renewable electricity for hydrogenation reactions used in manufacturing key fragrance ingredients. Aligned with the company’s commitment to Do More Good for people and planet, the site’s system can make 100 tons of clean hydrogen annually using renewable energy. It includes a built-in compressor to store hydrogen on-site — reducing the Life Cycle Assessment (LCA) of its products and supporting customers worldwide in achieving their decarbonization goals. This press release features multimedia. View the full release here: https://www
Samsung Bioepis Reaches Settlement Agreement for PYZCHIVA® (ustekinumab) in Europe6.11.2025 08:00:00 CET | Press release
Samsung Bioepis Co., Ltd. has signed a settlement and license agreement with Johnson & Johnson concerning the commercialization of PYZCHIVA®, a biosimilar to Stelara (ustekinumab)1, in Europe. The terms of the agreement remain confidential. Ustekinumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that prevents abnormal regulation of IL-12 and IL-23 associated with immune-mediated diseases. PYZCHIVA, developed by Samsung Bioepis, was approved as a biosimilar to Stelara (ustekinumab) by the European Commission (EC) in April 2024. PYZCHIVA is currently approved for the treatment of adults and paediatric patients from the age of 6 years and older with moderate to severe plaque psoriasis, adults with active psoriatic arthritis, adults with moderate to severely active Crohn’s disease. “This is a significant milestone for patients living with autoimmune diseases as we are making a step forward in improving access to this important biologic medicine for healthcare systems, pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom